Although the contribution of CCL2 to BC metastasis, especially lung metastasis, is rather clear, antagonists of CCL2 or its receptor CCR2 have not been successfully used in the clinical setting [24, 198, 199]. This evidence concerns the gene CCL2 and breast cancer.